在白血病干细胞中调节铁亡:从干细胞的保存到有针对性的分化策略
Zexin Wang1, Qiang Yang2, Yang Yang3
1School of Medicine, Mianyang Central Hospital, University of Electronic Science and Technology of China, Fucheng District, Mianyang City, 62100, Mianyang, Sichuan Province, China. wayen920326@163.com.
Stem cell reviews and reports
|November 1, 2025
概括
作为一种细胞死亡方法的铁灭,在急性髓性白血病中显示出针对耐药性白血病干细胞的前景. 一个新的模型预测了LSC铁亡的易感性,指导了更好的AML治疗的组合疗法.
科学领域:
- 在瘤学瘤学.
- 细胞死亡机制 细胞死亡机制
- 血液学 血液学 血液学
背景情况:
- 在急性髓性白血病 (AML) 中,白血病干细胞 (LSC) 表现出耐药性和持久性,阻碍有效治疗.
- 铁亡是一种受调节的细胞死亡途径,为向LSCs提供了潜在的治疗策略.
- 了解LSC铁灭菌耐药机制对于开发新型AML疗法至关重要.
研究的目的:
- 系统地审查LSC铁灭菌耐药性,重点关注铁代谢,脂质过氧化和抗氧化防御.
- 通过单细胞多组学数据和铁稳态调节器,提出LSC铁灭易感性的预测模型.
- 探索LSC铁质异质性及其与瘤微环境的相互作用,用于精确的AML治疗.
主要方法:
- 对LSC铁,铁代谢,脂质过氧化和抗氧化途径的文献进行系统审查.
- 开发一个整合TfR1,GPX4和FTH1的预测模型,用于评估LSC铁亡的易感性.
- 对LSC铁质异质性和瘤微环境相互作用的分析.
主要成果:
- 确定了铁稳态的关键调节剂 (TfR1,GPX4,FTH1) 影响LSC铁亡易感性.
- 标志着LSC铁性异质及其与瘤微环境的相互作用.
- 提出了一种新的治疗模式,将铁灭诱导剂与免疫疗法结合起来,以改善LSC清除.
结论:
- 铁化是一种有前途的策略,用于克服AML中的LSC药物耐药性.
- 整合铁稳态调节器的预测模型可以指导AML的精密治疗.
- 与铁致死诱导剂和免疫疗法的联合治疗可以改善LSC的根除,并减少可测量的残留疾病 (MRD).
相关概念视频
Regulation of Hematopoietic Stem Cells
3.9K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.9K
Lineage Commitment
4.1K
Commitment is the process whereby stem cells:
4.1K
Multipotency of Hematopoietic Stem Cells
3.8K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.8K
Cancer Stem Cells and Tumor Maintenance
5.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.9K
Stem Cell Therapy for Tissue Regeneration
4.6K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.6K
iPS Cell Differentiation
3.0K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.0K


